Introduction/Background Cervical cancer represents one of the most common cancers among women worldwide. According to FIGO 2018, FDG PET-CT became a part of the initial staging of the disease.

Rebound-thymus-hyperplasia (RTHP) with increased FDG accumulation in the thymus is a known phenomenon that is observed particularly among pediatric and young adult, secondary to recovery from stressors, such as surgery and chemotherapy.

To date, there isn`t much information regarding RTHP and its significance in women with cervical cancer. We aimed to investigate this phenomenon in cervical cancer patients.

Methodology Patients with cervical cancer who had been treated in Shamir-Medical-Center between 2010–2020 and undergone FGD PET-CT were collected respectively. We compared patients with and without RTHP.

The demographic, imaging and clinical characteristics were evaluated including histological type, stage at diagnosis, tumor size at diagnosis, treatment, SUV-max values, thymus size, time interval between treatments to scan, disease-free-survival and overall-survival.

The 3-dimensions and volume of the thymus, and SUV-max uptake were measured on PET-CT scans using PACS software (SECTRA IDS7, Sweden).

Results 106 patients included in the study with a mean-age of 55 years (range 27 - 88 years). 22 patients died during the follow-up with overall-survival rate of 79.2%. There was no measurable thymic tissue in 80 (75.5%) patients. In 26 patients the mean-thymic-volume calculated 2.33 cm3 (range 1.32 cm3 - 24 cm3 ). The SUV-max FDG-uptake measured with mean 2.0 (range 0.78- 4.9). We didn`t find any statistical significant differences between the groups.

Conclusion In our cervical cancer patients, we didn’t find any significant differences between those with or those without RTHP. Further research is needed to evaluate if there is any association between RTHP and cervical cancer in larger populations.

Disclosures There is no conflict interest.